PrEParing to End the HIV Epidemic — California’s Route as a Road Map for the United States | NEJM
Perspective from The New England Journal of Medicine — PrEParing to End the HIV Epidemic — California’s Route as a Road Map for the United States
Related Articles
Liraglutide for Children 6 to <12 Years of Age with Obesity — A Randomized Trial | NEJM
No medications are currently approved for the treatment of nonmonogenic, nonsyndromic obesity in children younger than 12 years of age. Although the use of liraglutide…
Liraglutide for Children 6 to <12 Years of Age with Obesity — A Randomized Trial | NEJM
No medications are currently approved for the treatment of nonmonogenic, nonsyndromic obesity in children younger than 12 years of age. Although the use of liraglutide…
Liraglutide for Children 6 to <12 Years of Age with Obesity — A Randomized Trial | NEJM
No medications are currently approved for the treatment of nonmonogenic, nonsyndromic obesity in children younger than 12 years of age. Although the use of liraglutide…
TikTok · NEJM
788 likes, 28 comments. “Come to rounds prepared. In our second video in partnership with @drglaucomflecken, a cardiologist quizzes a med student about a study…
Liraglutide for Children 6 to <12 Years of Age with Obesity — A Randomized Trial | NEJM
No medications are currently approved for the treatment of nonmonogenic, nonsyndromic obesity in children younger than 12 years of age. Although the use of liraglutide…
Influenza A(H5N1) Virus Infection in Two Dairy Farm Workers in Michigan | NEJM
In May 2024, two dairy farm workers in Michigan were identified as having influenza A(H5N1) virus infection. Conjunctivitis developed in one worker, and a respiratory…
Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for Mixed Hyperlipidemia | NEJM
Angiopoietin-like 3 (ANGPTL3) inhibits lipoprotein and endothelial lipases and hepatic uptake of triglyceride-rich lipoprotein remnants. ANGPTL3 loss-of-function carriers have lower levels of trigl…
Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia | NEJM
Persons with mixed hyperlipidemia are at risk for atherosclerotic cardiovascular disease due to an elevated non–high-density lipoprotein (HDL) cholesterol level, which is driven by remnant…
Asciminib in Newly Diagnosed Chronic Myeloid Leukemia | NEJM
Patients with newly diagnosed chronic myeloid leukemia (CML) need long-term therapy with high efficacy and safety. Asciminib, a BCR::ABL1 inhibitor specifically targeting the ABL myristoyl…
Case 27-2024: A 24-Year-Old Man with Pain and Dyspnea | NEJM
One hundred years ago, a 24-year-old man was admitted to the hospital because of fever, cough, and shortness of breath. The patient died on the…